<DOC>
	<DOCNO>NCT00192166</DOCNO>
	<brief_summary>- The primary objective study determine intranasally administer influenza virus vaccine , CAIV-T ) , administer concomitantly subcutaneously administer combination live , attenuated mumps , measles , rubella ( MMR ) virus vaccine child interfere immune response .</brief_summary>
	<brief_title>Trial Assess Safety , Efficacy , Tolerability Immunogenicity Influenza Virus Vaccine , Liquid Formulation ( CAIV-T ) , Administered Concomitantly With Combination Live , Attenuated , Mumps , Measles , Rubella Vaccine Healthy Children Aged 11 - 24 Months</brief_title>
	<detailed_description>- The primary objective study determine intranasally administer influenza virus vaccine , trivalent , type A B , live , cold-adapted ( CAIV-T ) , administer concomitantly subcutaneously administer combination live , attenuated mumps , measles , rubella ( MMR ) virus vaccine child age 11 less 24 month , interfere immune response measles , mumps , rubella component MMR vaccine . - To compare efficacy one season culture-confirmed influenza-illness cause community-acquired subtypes antigenically similar contain vaccine , child age least 11 month le 24 month enrollment , receive two dos CAIV-T receive placebo , concomitant administration combination live , attenuated MMR vaccine administer prior anticipate commencement influenza season .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>least 11 month age le 24 month age time first vaccination due receive first dose combine measles , mumps , rubella vaccine ( MMR ) good health determine medical history , physical examination clinical judgment whose parent ( ) /legal guardian ( ) provide write informed consent nature study explain , along parent ( ) /legal guardian ( ) , available duration trial ( approximately 8 month ) whose parent ( ) /legal guardian ( ) , could reach study staff postvaccination contact ( telephone , clinic home visit ) whose parent ( ) /legal guardian ( ) perceive unavailable difficult contact evaluation study visit study period serious chronic disease ( eg , sign cardiac renal failure severe malnutrition ) , include progressive neurological disease Down 's syndrome know cytogenetic disorder know suspected disease immune system receive immunosuppressive therapy , include systemic corticosteroid . Subjects receive high dos systemic corticosteroid give daily alternate day , 14 day , exclude vaccination corticosteroid therapy discontinue least one month . High dos define 2 mg/kg/day prednisolone equivalent , 20 mg/day child weigh 10 kg.38 receive , anticipated receive , blood product , include immunoglobulin , period 6 month prior vaccination conclusion study intent administer investigational vaccine agent one month prior enrollment conclusion study immunosuppressed immunocompromised individual living household , time prior entry study , receive dose influenza vaccine ( commercial investigational ) , time prior entry study , receive dose MMR vaccine individual component MMR vaccine ( commercial investigational ) anticipate receive subsequent dose MMR within 1 month receipt second dose CAIVT placebo document history hypersensitivity egg egg protein component CAIVT MMR receive aspirin ( acetylsalicylic acid ) aspirincontaining product 2 week prior vaccination use anticipate study medical condition opinion Investigator might interfere interpretation study result Note : Pregnancy person regular contact subject contraindication enrollment ongoing participation subject study .</criteria>
	<gender>All</gender>
	<minimum_age>11 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>